ArticleScience advances2023
Therapeutic blockade of ER stress and inflammation prevents NASH and progression to HCC.
Erratum issuedOpen access · goldAbstract read
In one paragraph
Article in Science advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 27 papers.
0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
7.9field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 34 citations in OpenAlex.
- Combination therapy with vitamin E and ertugliflozin in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a randomized clinical trial.Irish journal of medical science · 2025Trial
- Genetic and Pharmacological Targeting of Hsp72 Overexpression/Induction in an Alzheimer's Disease Mouse Model With Combined Amyloid and Tau Pathology.Journal of neuroscience research · 2026Article
- Refining therapeutic targeting of interleukin-6 by signalling mode selectivity.Nature reviews. Drug discovery · 2026Review
- Inhibiting endoplasmic reticulum stress and unfolded protein response: an effective strategy for chemoprevention of hepatocarcinogenesis.Molecular and cellular biochemistry · 2026Article
- Molecular mechanisms and pathogenesis of MASH.Nature · 2026Review
- GALNT18-Mediated O-Glycosylation Promotes Development of Nonalcoholic Steatohepatitis-Associated Hepatocellular Carcinoma Through Activation of EGR1/TGF-β1/Smad Signaling.Molecular biotechnology · 2026Article
- THEMIS attenuates MASH by suppressing disease-associated hepatocyte induction and hepatocyte senescence in mice.The Journal of clinical investigation · 2026Article
- Metabolic dysfunction-associated steatotic liver disease and steatohepatitis-associated hepatocarcinoma preclinical models.Nature reviews. Gastroenterology & hepatology · 2026Review
- Deficiency of PTEN Confers Hypersensitivity to Fatty Acid-Mediated ER Stress in Transformed Hepatocytes.International journal of molecular sciences · 2026Article
- Comparative analysis of renal dysfunction, immune remodeling, and gut microbiota profiles in dietary models of metabolic liver disease.BMC nephrology · 2026Article
- Translating Fibrosis to Malignancy: Biomarkers and Therapeutic Opportunities in Liver Fibrosis and Hepatocellular Carcinoma.Medical sciences (Basel, Switzerland) · 2026Review
- The inflammatory state of tumor peripheral liver tissue affects hepatocellular carcinoma progression and prognosis.Discover oncology · 2026Article
- NRF1 is upregulated by docosahexaenoic acid to ameliorate MASH through the inhibition of ER stress.Cell death & disease · 2026Article
- Bazedoxifene Targets gp130 Signaling to Suppress Fibroblast Activation in Pathological Cutaneous Fibrosis: Insights from Spatial Transcriptomics and scRNA-seq Data.International journal of biological sciences · 2026Article
- Blockade of Interleukin-6 Trans-signaling in the Presence of Certain Gut Microbiota Induces Mature-onset Obesity in Mice.Gastro hep advances · 2026Article
- ER Stress Ire1-Xbp1s Pathway Maintains Youthful Epidermal Basal Layer Through the Regulation of Cell Proliferation.Aging cell · 2025Article
- Ferroptosis in Human Diseases: Fundamental Roles and Emerging Therapeutic Perspectives.Antioxidants (Basel, Switzerland) · 2025Review
- The designer cytokine IC7Fc attenuates atherosclerosis development by targeting hyperlipidemia in mice.Science advances · 2025Article
- METTL3 knockout accelerates hepatocarcinogenesis via inhibiting endoplasmic reticulum stress response.FEBS open bio · 2025Article
- Exogenous hydrogen sulfide improves non-alcoholic fatty liver disease by inhibiting endoplasmic reticulum stress/NLRP3 inflammasome pathway.Molecular and cellular biochemistry · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
23 authors at 9 institutions in 5 countries.
Ebru BoslemMonash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Australia.ORCID 0000-0001-6123-4108
Saskia ReibeGarvan Institute of Medical Research, Sydney, Australia.ORCID 0000-0003-3638-7529
Rodrigo CarlessiHarry Perkins Institute of Medical Research, QEII Medical Centre and Centre for Medical Research, The University of Western Australia, Nedlands, WA 6009, Australia.ORCID 0000-0003-0038-7391
Benoit SmeuninxMonash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Australia.ORCID 0000-0002-0327-5726
Surafel TegegneMonash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Australia.ORCID 0000-0002-3280-9117
Casey L EganMonash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Australia.
Emma McLennanMonash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Australia.
Lauren V TerryMonash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Australia.
Max NobisGarvan Institute of Medical Research, Sydney, Australia.ORCID 0000-0002-1861-1390
Andre MuWellcome Sanger Institute, Cambridge, UK.
Cameron NowellMonash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Australia.ORCID 0000-0002-8662-9840
Neil HoradagodaFaculty of Veterinary Science, University of Sydney, Camden, Australia.ORCID 0000-0001-5530-777X
Darren C HenstridgeBaker Heart and Diabetes Institute, Melbourne, Victoria, Australia.
Natalie A MellettBaker Heart and Diabetes Institute, Melbourne, Victoria, Australia.
Paul TimpsonGarvan Institute of Medical Research, Sydney, Australia.ORCID 0000-0002-5514-7080
Matthew JonesHarry Perkins Institute of Medical Research, QEII Medical Centre and Centre for Medical Research, The University of Western Australia, Nedlands, WA 6009, Australia.
Elena DenisenkoHarry Perkins Institute of Medical Research, QEII Medical Centre and Centre for Medical Research, The University of Western Australia, Nedlands, WA 6009, Australia.
Alistair R R ForrestHarry Perkins Institute of Medical Research, QEII Medical Centre and Centre for Medical Research, The University of Western Australia, Nedlands, WA 6009, Australia.ORCID 0000-0003-4543-1675
Janina E E Tirnitz-ParkerCurtin Medical School, Curtin Health Innovation Research Institute, Curtin University, Bentley, WA 6102, Australia.ORCID 0000-0002-3558-5892
Peter J MeikleBaker Heart and Diabetes Institute, Melbourne, Victoria, Australia.ORCID 0000-0002-2593-4665
Stefan Rose-JohnDepartment of Biochemistry, Christian-Albrechts-Universität zu Kiel, Kiel, Germany.ORCID 0000-0002-7519-3279
Michael KarinDepartment of Pharmacology, University of California, San Diego, La Jolla, CA, USA.
Mark A FebbraioMonash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Australia.ORCID 0000-0002-9296-4418
Monash University · AUThe University of Western Australia · AUBaker Heart and Diabetes Institute · AUGarvan Institute of Medical Research · AUChristian-Albrechts-Universität zu Kiel · DECurtin University · AUEuropean Bioinformatics Institute · GBThe University of Sydney · AUUniversity of California San Diego · US
Funding
Yeast Genetics and Stress Response Genes-BiomedicalP42ES010337 · NIEHS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI TUKEY, ROBERT H · 2000 to 2022
$69.8MNF-kappaB and Mitochondrial Signals as Positive and Negative Regulators of InflammationR37AI043477 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Michael Karin · 2018 to 2026
$6.0MControl of Lipogenesis and Hepatic Steatosis by Caspase-2R01DK120714 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Michael Karin · 2019 to 2026
$4.0MRole of p62/SQSTM1 in obesity-induced liver cancerR01CA211794 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI KARIN, MICHAEL, MOSCAT, JORGE · 2017 to 2021
$3.6MER stress and UPR in non-alcoholic steatohepatitis and hepatocellular carcinomaR01CA198103 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI KAUFMAN, RANDAL J. · 2016 to 2020
$3.4MHighly penetrant and immunogenic mouse models of non-viral HCC that are suitable for evaluation of immune checkpoint inhibitorsR01CA234128 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI KARIN, MICHAEL · 2019 to 2023
$2.7MNCI NIH HHS R01 CA198103NCI NIH HHS R01 CA211794NCI NIH HHS R01 CA234128NIAID NIH HHS R37 AI043477NIDDK NIH HHS R01 DK120714NIEHS NIH HHS P42 ES010337
Abstract
The incidence of hepatocellular carcinoma (HCC) is rapidly rising largely because of increased obesity leading to nonalcoholic steatohepatitis (NASH), a known HCC risk factor. There are no approved treatments to treat NASH. Here, we first used single-nucleus RNA sequencing to characterize a mouse model that mimics human NASH-driven HCC, the
Indexed as
Carcinoma, HepatocellularLiver NeoplasmsNon-alcoholic Fatty Liver DiseaseAnimalsHepatocytesHumansInflammationMice
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.